505(b)(1)

LXP108

In response to tumor resistance, LXP108 with "multi-target synergistic blockade" strategy modulates multiple oncogenic pathways simultaneously to prevent tumor escape. This broad-spectrum mechanism is ideal for high-threshold cancers like pancreatic and liver cancer, offering a high-barrier, competitive solution against complex tumor microenvironments.

Therapeutic Area:

Solid Tumor

  • Renal Cancer
  • Liver Cancer
  • Pancreatic Cancer

Development Value

This strategy blocks multiple oncogenic pathways simultaneously to overcome resistance from compensatory escape mechanisms, suppressing tumor growth and improving treatment durability in refractory cancers.

Lates Progress

Development Stage

Preclinical

IND

Phase I

Phase II

Phase III

NDA

Phase I

Patents

Patents have been granted in Taiwan, the United States, Korea, China and Europe.

  • United States
  • Taiwan
  • Korea
  • China
  • Europe